ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog

Xoft breast IORT offers single-fraction therapy alternative to weeks of daily radiation, reducing resources needed and minimizing patients’ risk of COVID-19 exposure

ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog

Xoft breast IORT offers single-fraction therapy alternative to weeks of daily radiation, reducing resources needed and minimizing patients’ risk of COVID-19 exposure

Continue reading

Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment

Conference call today at 4:30 p.m. ET

NASHUA, N.H. – February 27, 2020 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating res... Continue reading

NASHUA, N.H., Feb. 13, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2019, after the market close, and host a conference call at 4:30 pm Eastern Time on Thursday, February 27, 2020.

Thursday, February 27th @ 4:30 pm ET

Domestic:

877-407-0784

International:

NASHUA, N.H., Feb. 12, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the 40th Annual Cowen Healthcare Conference, taking place March 2-4, 2020 in Boston, MA.

Presentation Details:

Date:

March 4, 2020

Time:

8:00am Eastern Time

Artificial intelligence (AI) seems to be everywhere. AI already helps us navigate traffic, conduct web searches, and shop online, and is rapidly establishing a foothold in healthcare. PINK Breast Center is proud to say we are already using AI to help our patients, with the first and only AI software for mammography the FDA has cleared.

Background

Breast cancer screening technologies have dramatically improved in recent years. One... Continue reading

First U.S. procedure follows matched pair study indicating a promising improvement in overall survival

NASHUA, N.H. – February 11, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using... Continue reading

iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer

NASHUA, N.H. – January 27, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will sho... Continue reading

iCAD traces its origins to 1984 ― a year of tremendous technological advancements: Dell Computers was founded, Apple introduced the Macintosh, and Sony released the Discman as the first portable CD player.[i],[ii],[iii] This year of inspiring innovation was the same year that Howard Howtek launched Howtek Inc., a technology company that initially specialized in developing, manufacturing, and marketing digitized systems and scanners. In 2001, the company began to specialize in computer-aided... Continue reading

Nashua, N.H. – January 13, 2020 – iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Nathaniel Dalton was appointed to its Board of Directors.

Mr. Dalton is one of the founders of the global asset management firm Affiliated Managers Group, Inc. (NYSE:AMG), where he remains a Director and Senior Advisor. Mr. Dalton held a range of executive positions at AMG, including General Counsel, Chief Operating Officer, President and Chief Executive O... Continue reading

World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system

NASHUA, NH -- December 4, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Breast Health Solution... Continue reading

Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time

NASHUA, N.H. and Chicago – December 2, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast Health Solutions suite including the expanded ProFound AI™ platform in the iCAD exhibition booths (#3929 in the sout... Continue reading

NASHUA, N.H., Nov. 26, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Piper Healthcare Conference, taking place December 3-5, 2019 in New York City.

Presentation Details:

Date: 

December 5, 2019

Continue reading

NASHUA, N.H., Nov. 18, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Canaccord Genuity MedTech & Diagnostics Forum, taking place Thursday, November 21st in New York City.

Presentation Details:

Date: 

Thursday, November 21, 2019

Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology

 Conference call today at 8:30 a.m. ET

NASHUA, N.H. – October 30, 2019 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions today reported its financial and operating results for the three and nine... Continue reading

With 1 in 8 women at risk of developing breast cancer in her lifetime[i], it’s important to know your personal risk and get screened regularly. Breast cancer screening has improved significantly in recent years, making it more important than ever for women to know about the latest advancements that can help doctors find cancers earlier, when they may be more easily treated. Before you book your next mammogram, talk to your doctor about your personal risks and what option is best for you.

Continue reading

NASHUA, N.H., Oct. 24, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter and nine-months ended September 30, 2019, before the market open, and host a conference call at 8:30am Eastern Time on Wednesday, October 30, 2019.

Wednesday, October 30th @ 8:30am ET

Domestic:

877-407-0784

iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference

NASHUA, N.H. and PARIS – October 7, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the full ProFound AI™ platform will be featured in the iCAD exhibition booth (#226A) at the Journées Francophones de Rad... Continue reading

Company to exhibit ProFound AI for 2D and 3D Mammography in Europe

Nashua, N.H. and Budapest, Hungary – October 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will exhibit the ProFound AI™ platform, including ProFound AI™ for 2D Mammography and ProFound AI™ for Digital Breast Tomosynthesis (DBT) in the iCAD exhibition booth (#13) at the Eu... Continue reading

Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers

NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electronic... Continue reading